Our findings also demonstrate that these drugs targeting CTGF could not only inhibit the function of CAFs in promoting GC migration, but they could also reverse the inhibitory effects of co-culturing with CAFs on the expression of E-cadherin and ZO-1 in GC cells (Fig. 5A and B). The gene discussed is CCN2; the disease is gastric cancer.